Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer

This publication has 37 references indexed in Scilit:

• Development and Validation of a Multimodal Artificial Intelligence–derived Digital Pathology–based Biomarker Predicting Metastasis Among Patients with Biochemical Recurrence After Radical Prostatectomy in NRG/RTOG Trials
  European Urology, 2025
• LBA86 Randomised phase III trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)
  Annals of Oncology, 2025
• ESMO basic requirements for AI-based biomarkers in oncology (EBAI)
  Annals of Oncology, 2025
• Digital Pathology–based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer
  European Urology Oncology, 2024
• Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial
  European Urology Oncology, 2024
• Meta-analysis of Individual Patient-level Data for a Multimodal Artificial Intelligence Biomarker in High-risk Prostate Cancer: Results from Six NRG/RTOG Phase 3 Randomized Trials
  European Urology, 2024
• Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials
  European Urology, 2024
• External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial
  European Urology Oncology, 2024
• Increasing rates of NCCN high and very high‐risk prostate cancer versus number of prostate biopsy cores
  The Prostate, 2021
• Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases
  Journal of Urology, 2018